Loeb & Loeb Advises Virax Biolabs Group Limited in its Initial Public Offering On the Nasdaq Capital Market

Loeb & Loeb acted as issuer counsel to the biotechnology company Virax Biolabs Group Limited in its initial public offering of 1,350,000 ordinary shares at a price of $5.00 per share on the Nasdaq Capital Market under the ticker symbol “VRAX.”

Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology. The company is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats.

The Loeb & Loeb team was led by Capital Markets & Corporate partner Lawrence Venick and included Capital Markets associates Michael Tsang and Rongwei Xie.